These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 20394182)
1. Quality of life in Parkinson's disease patients following adjunctive tolcapone therapy: results of an open-label, multicenter, community-based trial. Sethi K; Factor S; Watts R CNS Spectr; 2010 Jan; 15(1):27-32. PubMed ID: 20394182 [TBL] [Abstract][Full Text] [Related]
2. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K; Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133 [TBL] [Abstract][Full Text] [Related]
3. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116 [TBL] [Abstract][Full Text] [Related]
4. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Kurth MC; Adler CH; Hilaire MS; Singer C; Waters C; LeWitt P; Chernik DA; Dorflinger EE; Yoo K Neurology; 1997 Jan; 48(1):81-7. PubMed ID: 9008498 [TBL] [Abstract][Full Text] [Related]
5. Tolcapone: a review of its use in the management of Parkinson's disease. Keating GM; Lyseng-Williamson KA CNS Drugs; 2005; 19(2):165-84. PubMed ID: 15697329 [TBL] [Abstract][Full Text] [Related]
6. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Koller W; Lees A; Doder M; Hely M; Mov Disord; 2001 Sep; 16(5):858-66. PubMed ID: 11746615 [TBL] [Abstract][Full Text] [Related]
7. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease. Deane KH; Spieker S; Clarke CE Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118 [TBL] [Abstract][Full Text] [Related]
8. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Deane KH; Spieker S; Clarke CE Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119 [TBL] [Abstract][Full Text] [Related]
9. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084 [TBL] [Abstract][Full Text] [Related]
10. Utility of tolcapone in fluctuating Parkinson's disease. Stocchi F; De Pandis MF Clin Interv Aging; 2006; 1(4):317-25. PubMed ID: 18046910 [TBL] [Abstract][Full Text] [Related]
11. Tolcapone: a novel approach to Parkinson's disease. Micek ST; Ernst ME Am J Health Syst Pharm; 1999 Nov; 56(21):2195-205. PubMed ID: 10565698 [TBL] [Abstract][Full Text] [Related]
12. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522 [TBL] [Abstract][Full Text] [Related]
13. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Adler CH; Singer C; O'Brien C; Hauser RA; Lew MF; Marek KL; Dorflinger E; Pedder S; Deptula D; Yoo K Arch Neurol; 1998 Aug; 55(8):1089-95. PubMed ID: 9708959 [TBL] [Abstract][Full Text] [Related]
14. Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone. Welsh MD; Dorflinger E; Chernik D; Waters C Mov Disord; 2000 May; 15(3):497-502. PubMed ID: 10830415 [TBL] [Abstract][Full Text] [Related]
15. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Guay DR Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075 [TBL] [Abstract][Full Text] [Related]
16. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Factor SA; Molho ES; Feustel PJ; Brown DL; Evans SM Clin Neuropharmacol; 2001; 24(5):295-9. PubMed ID: 11586115 [TBL] [Abstract][Full Text] [Related]